Senti Biosciences, Inc. 8-K

What Happened
Senti Biosciences Holdings, Inc. announced on April 27, 2026 that it entered a Securities Purchase Agreement to issue up to $40.0 million in aggregate principal of senior secured convertible notes through its subsidiary Senti Holdings, in a private placement to an investor affiliated with Celadon Partners (the Company’s largest stockholder). The deal contemplates an initial $10.0 million tranche (subject to closing conditions; the Company completed a required holding‑company reorganization on April 24, 2026) and up to $30.0 million of additional notes at Celadon’s discretion, conditioned on certain closings and potential definitive documents for a contingent‑value-right (CVR) transaction.

Key Details

• Agreement date: April 27, 2026; holding‑company reorganization completed April 24, 2026.
• Financing size: up to $40.0M total — $10.0M initial notes; up to $30.0M additional notes contingent on Celadon’s election and further conditions.
• CVR: any related CVR Transaction could create a contingent value right that pays up to $60.0M in cash tied to regulatory and sales milestones for SENTI‑202.
• Terms & covenants: proceeds to be used mainly for corporate purposes and to advance CMC/clinical trials of SENTI‑202; Celadon receives 3.0% of the principal as a placement fee; company must seek stockholder approval (by Aug 31, 2026) to issue shares underlying the notes without an exchange cap, and Celadon agreed to vote in favor.

Why It Matters
This transaction creates a new senior secured convertible debt obligation and provides near‑term funding (initial $10M) to support development of the company’s lead candidate, SENTI‑202. The financing is with an investor affiliated with the company’s largest shareholder, which may facilitate execution but is a related‑party arrangement. Additional funding (up to $30M) and a possible CVR tied to SENTI‑202 milestones could further affect the company’s capital structure and potential cash payouts; issuance beyond the current exchange cap requires shareholder approval. Retail investors should note the potential for future dilution if the notes convert, the creation of a secured creditor claim, and that material additional documents and a proxy will be filed with the SEC for any Subject Transactions.